Two new hyaluronic acid fillers expand Merz's portfolio with deeper, more targeted placement options.
Merz has won FDA approval for BELOTERO VOLUME (+) and BELOTERO INTENSE (+), two new hyaluronic acid fillers that round out its injectable lineup. VOLUME targets deeper facial volume loss, while INTENSE addresses moderate-to-severe lines and wrinkles with a denser formulation.
The approvals mark a strategic move to compete more directly with Galderma's Restylane and AbbVie's Juvéderm across multiple depth planes. Merz already owns the BELOTERO family (Balance, Soft, Hydro) and has built loyalty through its Alle rebate program. These additions let practices offer a full volumization strategy without switching manufacturers—a meaningful advantage in per-unit economics and inventory management.
Two new HA fillers let practices build full volumization strategy without switching manufacturers.
For owners, the play is straightforward: deeper product options reduce reliance on biostimulators like Radiesse or Sculptra for volume, keeping margin dollars in the HA category where per-syringe spreads remain competitive.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
